Additive interaction of leucine and Isoleucine with SFA16:0 for the risk of GDM.
| . | Unadjusted OR/estimate (95% CI) . | P value . | Adjusted OR/estimate (95% CI)a . | P value . |
|---|---|---|---|---|
| Leu and SFA16:0 | ||||
| Additive interaction models | ||||
| Leu < 153.3 & SFA16:0 < 17.1 nmol/mL | Reference | Reference | ||
| Leu < 153.3 & SFA16:0 ≥ 17.1 nmol/mL | 2.02 (1.27-3.21) | 0.0028 | 2.22 (1.33-3.72) | 0.0024 |
| Leu ≥ 153.3 & SFA16:0 < 17.1 nmol/mL | 1.30 (0.71-2.37) | 0.3899 | 1.45 (0.74-2.84) | 0.2815 |
| Leu ≥ 153.3 & SFA16:0 ≥ 17.1 nmol/mL | 3.99 (2.21-7.19) | < 0.0001 | 4.56 (2.37-8.75) | < 0.0001 |
| Measures of additive interactionb | ||||
| RERI | 1.66(-0.42 to 3.75) | - | 1.89 (-0.78 to 4.56) | - |
| AP | 0.42 (0.06 to 0.78) | - | 0.41 (0.01 to 0.82) | - |
| SI | 2.26 (0.83 to 6.15) | - | 2.13 (0.77 to 5.87) | - |
| Ile and SFA16:0 | ||||
| Additive interaction models | ||||
| Ile < 36.2 & SFA16:0 < 17.1 nmol/mL | Reference | Reference | ||
| Ile < 36.2 & SFA16:0 ≥ 17.1 nmol/mL | 1.99 (1.27-3.11) | 0.0025 | 2.12 (1.29-3.48) | 0.0029 |
| Ile ≥ 36.2 & SFA16:0 < 17.1 nmol/mL | 1.28 (0.72-2.28) | 0.4018 | 1.27 (0.66-2.44) | 0.4768 |
| Ile ≥ 36.2 & SFA16:0 ≥ 17.1 nmol/mL | 3.96 (2.22-7.04) | < 0.0001 | 4.41 (2.30-8.43) | < 0.0001 |
| Measures of additive interactionb | ||||
| RERI | 1.69 (-0.33 to 3.70) | - | 2.01 (-0.53 to 4.56) | - |
| AP | 0.43 (0.08 to 0.77) | - | 0.46 (0.09 to 0.82) | - |
| SI | 2.33 (0.88 to 6.16) | - | 2.45 (0.86 to 6.93) | - |
| . | Unadjusted OR/estimate (95% CI) . | P value . | Adjusted OR/estimate (95% CI)a . | P value . |
|---|---|---|---|---|
| Leu and SFA16:0 | ||||
| Additive interaction models | ||||
| Leu < 153.3 & SFA16:0 < 17.1 nmol/mL | Reference | Reference | ||
| Leu < 153.3 & SFA16:0 ≥ 17.1 nmol/mL | 2.02 (1.27-3.21) | 0.0028 | 2.22 (1.33-3.72) | 0.0024 |
| Leu ≥ 153.3 & SFA16:0 < 17.1 nmol/mL | 1.30 (0.71-2.37) | 0.3899 | 1.45 (0.74-2.84) | 0.2815 |
| Leu ≥ 153.3 & SFA16:0 ≥ 17.1 nmol/mL | 3.99 (2.21-7.19) | < 0.0001 | 4.56 (2.37-8.75) | < 0.0001 |
| Measures of additive interactionb | ||||
| RERI | 1.66(-0.42 to 3.75) | - | 1.89 (-0.78 to 4.56) | - |
| AP | 0.42 (0.06 to 0.78) | - | 0.41 (0.01 to 0.82) | - |
| SI | 2.26 (0.83 to 6.15) | - | 2.13 (0.77 to 5.87) | - |
| Ile and SFA16:0 | ||||
| Additive interaction models | ||||
| Ile < 36.2 & SFA16:0 < 17.1 nmol/mL | Reference | Reference | ||
| Ile < 36.2 & SFA16:0 ≥ 17.1 nmol/mL | 1.99 (1.27-3.11) | 0.0025 | 2.12 (1.29-3.48) | 0.0029 |
| Ile ≥ 36.2 & SFA16:0 < 17.1 nmol/mL | 1.28 (0.72-2.28) | 0.4018 | 1.27 (0.66-2.44) | 0.4768 |
| Ile ≥ 36.2 & SFA16:0 ≥ 17.1 nmol/mL | 3.96 (2.22-7.04) | < 0.0001 | 4.41 (2.30-8.43) | < 0.0001 |
| Measures of additive interactionb | ||||
| RERI | 1.69 (-0.33 to 3.70) | - | 2.01 (-0.53 to 4.56) | - |
| AP | 0.43 (0.08 to 0.77) | - | 0.46 (0.09 to 0.82) | - |
| SI | 2.33 (0.88 to 6.16) | - | 2.45 (0.86 to 6.93) | - |
Abbreviations: AP, attributable proportion due to interaction; GDM, gestational diabetes mellitus; Ile, isoleucine; Leu, leucine; RERI, relative excess risk due to interaction; SFA, saturated fatty acid; SI, synergy index.
aAdjusted for prepregnancy body mass index, systolic blood pressure, Han nationality, family history of diabetes in first-degree relatives, parity, education attainment, current smoker before or during pregnancy, alcohol drinker before or during pregnancy, and weight gain to glucose challenge test.
bStatistically significant, with RERI > 0, AP > 0, or SI > 1 indicating significant additive interaction.
Additive interaction of leucine and Isoleucine with SFA16:0 for the risk of GDM.
| . | Unadjusted OR/estimate (95% CI) . | P value . | Adjusted OR/estimate (95% CI)a . | P value . |
|---|---|---|---|---|
| Leu and SFA16:0 | ||||
| Additive interaction models | ||||
| Leu < 153.3 & SFA16:0 < 17.1 nmol/mL | Reference | Reference | ||
| Leu < 153.3 & SFA16:0 ≥ 17.1 nmol/mL | 2.02 (1.27-3.21) | 0.0028 | 2.22 (1.33-3.72) | 0.0024 |
| Leu ≥ 153.3 & SFA16:0 < 17.1 nmol/mL | 1.30 (0.71-2.37) | 0.3899 | 1.45 (0.74-2.84) | 0.2815 |
| Leu ≥ 153.3 & SFA16:0 ≥ 17.1 nmol/mL | 3.99 (2.21-7.19) | < 0.0001 | 4.56 (2.37-8.75) | < 0.0001 |
| Measures of additive interactionb | ||||
| RERI | 1.66(-0.42 to 3.75) | - | 1.89 (-0.78 to 4.56) | - |
| AP | 0.42 (0.06 to 0.78) | - | 0.41 (0.01 to 0.82) | - |
| SI | 2.26 (0.83 to 6.15) | - | 2.13 (0.77 to 5.87) | - |
| Ile and SFA16:0 | ||||
| Additive interaction models | ||||
| Ile < 36.2 & SFA16:0 < 17.1 nmol/mL | Reference | Reference | ||
| Ile < 36.2 & SFA16:0 ≥ 17.1 nmol/mL | 1.99 (1.27-3.11) | 0.0025 | 2.12 (1.29-3.48) | 0.0029 |
| Ile ≥ 36.2 & SFA16:0 < 17.1 nmol/mL | 1.28 (0.72-2.28) | 0.4018 | 1.27 (0.66-2.44) | 0.4768 |
| Ile ≥ 36.2 & SFA16:0 ≥ 17.1 nmol/mL | 3.96 (2.22-7.04) | < 0.0001 | 4.41 (2.30-8.43) | < 0.0001 |
| Measures of additive interactionb | ||||
| RERI | 1.69 (-0.33 to 3.70) | - | 2.01 (-0.53 to 4.56) | - |
| AP | 0.43 (0.08 to 0.77) | - | 0.46 (0.09 to 0.82) | - |
| SI | 2.33 (0.88 to 6.16) | - | 2.45 (0.86 to 6.93) | - |
| . | Unadjusted OR/estimate (95% CI) . | P value . | Adjusted OR/estimate (95% CI)a . | P value . |
|---|---|---|---|---|
| Leu and SFA16:0 | ||||
| Additive interaction models | ||||
| Leu < 153.3 & SFA16:0 < 17.1 nmol/mL | Reference | Reference | ||
| Leu < 153.3 & SFA16:0 ≥ 17.1 nmol/mL | 2.02 (1.27-3.21) | 0.0028 | 2.22 (1.33-3.72) | 0.0024 |
| Leu ≥ 153.3 & SFA16:0 < 17.1 nmol/mL | 1.30 (0.71-2.37) | 0.3899 | 1.45 (0.74-2.84) | 0.2815 |
| Leu ≥ 153.3 & SFA16:0 ≥ 17.1 nmol/mL | 3.99 (2.21-7.19) | < 0.0001 | 4.56 (2.37-8.75) | < 0.0001 |
| Measures of additive interactionb | ||||
| RERI | 1.66(-0.42 to 3.75) | - | 1.89 (-0.78 to 4.56) | - |
| AP | 0.42 (0.06 to 0.78) | - | 0.41 (0.01 to 0.82) | - |
| SI | 2.26 (0.83 to 6.15) | - | 2.13 (0.77 to 5.87) | - |
| Ile and SFA16:0 | ||||
| Additive interaction models | ||||
| Ile < 36.2 & SFA16:0 < 17.1 nmol/mL | Reference | Reference | ||
| Ile < 36.2 & SFA16:0 ≥ 17.1 nmol/mL | 1.99 (1.27-3.11) | 0.0025 | 2.12 (1.29-3.48) | 0.0029 |
| Ile ≥ 36.2 & SFA16:0 < 17.1 nmol/mL | 1.28 (0.72-2.28) | 0.4018 | 1.27 (0.66-2.44) | 0.4768 |
| Ile ≥ 36.2 & SFA16:0 ≥ 17.1 nmol/mL | 3.96 (2.22-7.04) | < 0.0001 | 4.41 (2.30-8.43) | < 0.0001 |
| Measures of additive interactionb | ||||
| RERI | 1.69 (-0.33 to 3.70) | - | 2.01 (-0.53 to 4.56) | - |
| AP | 0.43 (0.08 to 0.77) | - | 0.46 (0.09 to 0.82) | - |
| SI | 2.33 (0.88 to 6.16) | - | 2.45 (0.86 to 6.93) | - |
Abbreviations: AP, attributable proportion due to interaction; GDM, gestational diabetes mellitus; Ile, isoleucine; Leu, leucine; RERI, relative excess risk due to interaction; SFA, saturated fatty acid; SI, synergy index.
aAdjusted for prepregnancy body mass index, systolic blood pressure, Han nationality, family history of diabetes in first-degree relatives, parity, education attainment, current smoker before or during pregnancy, alcohol drinker before or during pregnancy, and weight gain to glucose challenge test.
bStatistically significant, with RERI > 0, AP > 0, or SI > 1 indicating significant additive interaction.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
